glp-1 news oct 9 2025 ISPOR 2025: Exploring reasons for discontinuation GLP-1 Weight-Loss Drug Demonstration Begins
Description
Its mechanism involves enhancing insulin secretion, suppressing glucagon, and slowing gastric emptying, all contributing to a prolonged feeling of fullness
These changes create a foundation that minimizes gastrointestinal distress once the medication kicks in
Plan sponsors will also see lower costs through the program, Evernorth said, and can ensure that employees and other plan members receive the medications that best meet their needs
Theres also a lack of information about any possible effects on a breastfed baby
